QURE
NASD uniQure N.V.$23.29 ↓ -0.08 (-0.34%) Trading Down from the previous close of $23.37, $0.43 below the day’s high of $23.72
- YTD change
- -2.67%
- vs 20-day SMA
- -42.40%
- vs 200-day SMA
- -21.61%
Price ranges
Price & Performance
+6.21 (+36.19%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 71.8% away from all-time highs of $82.49
- QURE is down 3% since the beginning of the year
- QURE is down 57% over the past 12 months
- QURE is down 50% over the past 1 month
- 15% of all QURE investors are betting against QURE
QURE reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -57.1%.
- Previous minute
- +$0.03
- Last hour
- -$0.13
- Last 5 days
- -39.22%
- vs 8-day SMA
- -32.43%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
